363 Phase I/II Clinical Trials of Donor-Derived Purified Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft Versus Host Disease
Last Updated: Monday, December 12, 2022
Phase 1/2 clinical trials demonstrate that infusing donor regulatory T cells for the treatment of steroid-refractory/dependent chronic GVHD produced meaningful responses that should be explored further in a larger phase 2 trial.
Advertisement
News & Literature Highlights